字體:小 中 大 |
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 2025/12/23 03:14:49瀏覽39|回應0|推薦0 | |||||||||||||||||||||||||||||||||||||||||||||
跟著城市嚮導「老臺北胃」,用味道認識臺北很多朋友來臺北, 我怎麼選出這 10 大臺北小吃?在臺北, 一吃就知道:這就是臺灣味燒烤、火鍋很好吃, 不只是好吃,而是有「臺北日常感」臺北的小吃迷人,
吃完之後,你會記得臺北最後一個標準很簡單。 接下來的 10 樣臺北小吃, 第 1 家:饌堂-黑金滷肉飯(雙連店)|一碗就懂臺灣人的日常
如果只能用一道料理, 為什麼第一站,我會選饌堂? 不只是好吃,而是「現在的臺北感」 老臺北胃的帶路小提醒
這不是那種吃完會驚呼「哇!」的料理, 地址:103臺北市大同區雙連街55號1樓 電話:0225501379 第 2 家:富宏牛肉麵|臺北深夜也醒著的一碗熱湯
如果說滷肉飯代表的是臺灣人的日常, 為什麼老臺北胃會帶你來吃富宏? 不分時間,任何時候都適合的一碗麵 老臺北胃的帶路小提醒
這不是精緻料理, 地址:108臺北市萬華區洛陽街67號 電話:0223713028 菜單:https://www.facebook.com/pages/富宏牛肉麵-原建宏牛肉麵/ 第 3 家:士林夜市・吉彖皮蛋涼麵|臺北夏天最有記憶點的一口清爽
如果你在夏天來到臺北, 為什麼在夜市,我會帶你吃涼麵? 皮蛋,是靈魂,也是臺灣味的關鍵 老臺北胃的帶路小提醒
這不是華麗的小吃, 原來臺北的小吃,連氣候都一起考慮進去了。 地址:111臺北市士林區基河路114號 電話:0981014155 菜單:https://www.facebook.com/profile.php?id=100064238763064 第 4 家:胖老闆誠意肉粥|臺北人深夜最踏實的一碗粥
如果你問我, 為什麼這一碗粥,會被叫做「誠意」? 這不是觀光小吃,而是臺北人的生活片段
這些畫面, 老臺北胃的帶路小提醒
這不是為了拍照而存在的小吃, 地址:10491臺北市中山區長春路89-3號 電話:0913806139 第 5 家:圓環邊蚵仔煎|夜市裡最不能缺席的臺灣經典
如果要選一道 為什麼蚵仔煎,這麼能代表臺灣? 圓環邊,吃的是記憶感 老臺北胃的帶路小提醒
蚵仔煎不是細嚼慢嚥的料理, 地址:103臺北市大同區寧夏路46號 電話:0225580198 菜單:https://oystera.com.tw/menu 第 6 家:阿淑清蒸肉圓|第一次吃肉圓,就該從這裡開始
說到臺灣小吃, 清蒸肉圓,和你想像的不一樣 為什麼我會推薦給第一次來臺北的旅客? 老臺北胃的帶路小提醒
這不是夜市裡熱鬧喧囂的料理, 地址:242新北市新莊區復興路一段141號 電話:0229975505 第 7 家:胡記米粉湯|一碗最貼近臺北早晨的味道
如果說前面幾樣小吃, 為什麼米粉湯,這麼「臺北」? 配菜,才是這一碗的靈魂延伸 老臺北胃的帶路小提醒
這不是為了觀光而存在的小吃, 地址:106臺北市大安區大安路一段9號1樓 電話:0227212120 第 8 家:藍家割包|一口咬下的臺灣街頭記憶
如果要選一道 割包,為什麼被叫做「臺灣漢堡」? 藍家割包不是走浮誇路線, 老臺北胃的帶路小提醒
割包不是精緻料理, 地址:100臺北市中正區羅斯福路三段316巷8弄3號 電話:0223682060 菜單:https://instagram.com/lan_jia_gua_bao?utm_medium=copy_link 第 9 家:御品元冰火湯圓|臺北夜晚最溫柔的一碗甜
吃了一整天的臺北小吃, 為什麼叫「冰火」?這碗湯圓的關鍵就在這裡 這是一碗,會讓人慢下來的甜點 老臺北胃的帶路小提醒
這不是為了拍照而存在的甜點, 地址:106臺北市大安區通化街39巷50弄31號 電話:0955861816 菜單:https://instagram.com/lan_jia_gua_bao 第 10 家:頃刻間綠豆沙牛奶專賣店|把臺北的味道,留在最後一口清甜
走到這一站, 綠豆沙牛奶,為什麼這麼「臺灣」? 為什麼我會用它當作最後一站? 老臺北胃的帶路小提醒
這一杯, 地址:111臺北市士林區小北街1號 電話:0228818619 菜單:https://instagram.com/chill_out_moment?igshid=YmMyMTA2M2Y= 如果只有 3 天的自助旅行在臺北,怎麼吃這 10 家?第一次來臺北, 臺北 3 天小吃推薦行程表(老臺北胃版本)
雖然每個小吃的地點都有一點距離,但是你也知道,好吃的小吃,是值得你花一點時間前往品嘗
當你照著這 3 天走完, 老臺北胃帶路|這 10 口,就是我心中的臺北
寫到這裡, 如果你問我,
如果你是第一次來臺北, 富宏牛肉麵男生會吃得飽嗎? 走完這 10 家, 你可能會發現一件事阿淑清蒸肉圓吃過會回訪嗎? 臺北的小吃,其實不急著被你記住。 它們就安靜地存在在街角、夜市、轉彎處,阿淑清蒸肉圓容易接受嗎? 等你有一天,再回到這座城市。士林夜市-吉彖皮蛋涼麵適合第一次吃嗎? 如果你是第一次來臺北,藍家割包怎麼點比較好? 希望這份「老臺北胃帶路」的清單, 能幫你少一點猶豫、多一點安心。 不用擔心踩雷,頃刻間綠豆沙牛奶專賣店值得專程去吃嗎? 也不用為了排行而奔波,御品元冰火湯圓會不會太甜? 只要照著節奏走, 你就會吃到屬於自己的臺北味道。 而如果你已經來過臺北, 那更希望這篇文章,圓環邊蚵仔煎原味就好嗎? 能帶你走進那些 你可能錯過、卻一直都在的日常小吃。 因為真正迷人的旅行, 從來不是把清單全部打勾, 而是某一天, 你突然想起那碗飯、那口湯、那杯甜,御品元冰火湯圓推薦嗎? 然後在心裡對自己說一句:藍家割包男生會吃得飽嗎? 「下次再去臺北,還想再吃一次。」 把這篇文章存起來、分享給一起旅行的人, 或是在規劃行程時,再回來看看。 讓味道,成為你認識臺北的方式。 下一次來臺北, 別急著走遠。 老臺北胃,胖老闆誠意肉粥會不會太甜? 會一直在這些地方, 等你再回來。 It might be hard to believe, but this is a picture of a memory. In this image, the blue dots are positive memory cells, and the red dots are negative memory cells. Memories exist in the brain as networks of cells called engrams, and are stored and processed all over the brain. The memories shown here are located in the hippocampus of a mouse. Credit: Photo by Stephanie Grella Neuroscientists show that it’s possible to turn the volume down on a negative memory by stimulating other, happier ones. Even though you may not realize it, each time you recall a memory—such as your first time riding a bike or walking into your high school prom—your brain changes the memory ever so slightly. It’s almost like adding an Instagram filter, with details being filled in and information being updated or lost with each recall. “We’re inadvertently applying filters to our past experiences,” says Steve Ramirez (CAS’10), a Boston University (BU) neuroscientist. Even though a filtered memory is different from the original, for the most part, you can tell what that basic picture is, he says. “Memory is less of a video recording of the past, and more reconstructive,” says Ramirez, a BU College of Arts & Sciences assistant professor of psychological and brain sciences. It is both a blessing and a curse that memory is malleable in nature. If we remember false details, it is bad. However, especially for memories of something scary or traumatic, it’s good that our brains have the natural ability to mold and update memories to make them less potent. What if it’s possible to use the malleable nature of our memories to our advantage, as a way to cure mental health disorders like depression and post-traumatic stress disorder (PTSD)? Ramirez and his research team are actively pursuing this goal. And after years of studying memory in mice, they’ve found not only where the brain stores positive and negative memories, but also how to turn the volume down on negative memories by artificially stimulating other, happier ones. “Our million-dollar idea is, what if a solution for some of these mental disorders already exists in the brain? And what if memory is one way of getting there?” Ramirez asks. In two new scientific papers, he and his team demonstrate the power of our emotional memories and how our experiences—and the way we process them—leave actual physical footprints on the brain. Mapping Positive and Negative Memories One of the most important steps toward using memory to treat memory-related disorders is understanding where positive and negative memories exist in the brain, and how to distinguish between the two. Memories are stored in all different areas across the brain, and the individual memories themselves exist as networks of cells called engrams. Ramirez’s lab is particularly interested in the networks of memories located in the brain’s hippocampus, a cashew-shaped structure that stores sensory and emotional information important for forming and retrieving memories. The term “engram” was coined in 1904 by memory researcher Richard Semon. An engram is a unit of cognitive information imprinted in a physical substance, theorized to be the means by which memories are stored as biophysical or biochemical changes in the brain or other biological tissue, in response to external stimuli. In a new paper published in Nature Communications Biology, Ramirez, lead author Monika Shpokayte (MED’26), and a team of BU neuroscientists mapped out the key molecular and genetic differences between positive and negative memories. They found that the two are actually strikingly distinct on multiple levels. It turns out that emotional memories, like a positive or negative memory, are physically distinct from other types of brain cells—and distinct from each other. “That’s pretty wild because it suggests that these positive and negative memories have their own separate real estate in the brain,” says Ramirez, who’s also a member of BU’s Center for Systems Neuroscience. The study authors found that positive and negative memory cells are different from each other in almost every way—they are mostly stored in different regions of the hippocampus, they communicate with other cells using different types of pathways, and the molecular machinery in both types of cells seems to be distinct. “So, there’s [potentially] a molecular basis for differentiating between positive and negative memories in the brain,” Ramirez says. “We now have a bunch of markers that we know differentiate positive from negative in the hippocampus.” Seeing and labeling positive and negative memories is only possible with the use of an advanced neuroscience tool, called optogenetics. This is a way to trick brain cell receptors to respond to light—researchers shine a harmless laser light into the brain to turn on cells that have been given a receptor that responds to light. They can also color-code positive and negative memories by inserting a fluorescent protein that is stimulated by light, so that positive memory cell networks glow green, for example, and negative cell networks glow red or blue. In this image, the red cells are a fear memory. After artificially activating another, more pleasant memory, those red cells turned into the blue cells, which represent the altered, less powerful fear memory. This demonstrates that the original memory has been altered by their memory manipulation technique, according to lead study author Stephanie Grella. Credit: Photo by Stephanie Grella Rewiring Bad Memories Before the researchers label a memory in a mouse, they first have to make the memory. To do this, they expose the rodents to a universally good or unpleasant experience—a positive experience could be nibbling on some tasty cheese or socializing with other mice; a negative experience could be receiving a mild but surprising electrical shock to the feet. Once a new memory is formed, the scientists can find the network of cells that hold on to that experience, and have them glow a certain color. Once they can see the memory, researchers can use laser light to artificially activate those memory cells—and, as Ramirez’s team has also discovered, rewrite the negative memories. In a paper published in Nature Communications, they found that artificial activation of a positive experience permanently rewrote a negative experience, dialing the emotional intensity of the bad memory down. The researchers had the mice recall a negative experience, and during the fear memory recall, they artificially reactivated a group of positive memory cells. The competing positive memory, according to the paper, updated the fear memory, reducing the fear response at the time and long after the memory was activated. The study builds on previous work from Ramirez’s lab that found it’s possible to artificially manipulate past memories. Activating a positive memory was the most powerful way to update a negative memory, but the team also found it’s not the only way. Instead of targeting just positive memory cells, they also tried activating a neutral memory—some standard, boring experience for an animal—and then tried activating the whole hippocampus, finding that both were effective. “If you stimulate a lot of cells not necessarily tied to any type of memory, that can cause enough interference to disrupt the fear memory,” says Stephanie Grella, lead author and a former postdoctoral fellow in the Ramirez Lab who recently started the Memory & Neuromodulatory Mechanisms Lab at Loyola University. Even though artificially activating memories is not possible to do in humans, the findings could still translate to clinical settings, Grella says. “Because you can ask the person, ‘Can you remember something negative, can you remember something positive?’” she says—questions you can’t ask a mouse. She suggests that it could be possible to override the impacts of a negative memory, one that has affected a person’s mental state, by having a person recall the bad memory, and correctly timing a vivid recall of a positive one in a therapeutic setting. “We know that memories are malleable,” Grella says. “??One of the things that we found in this paper was that the timing of the stimulation was really critical.” The Quest for Game Changers For other, more intensive types of treatment for severe depression and PTSD, Grella suggests that it could eventually be possible to stimulate large swaths of the hippocampus with tools like transcranial magnetic stimulation or deep brain stimulation—an invasive procedure—to help people overcome these memory-related disorders. Ramirez points out that more and more neuroscientists have started to embrace experimental treatments involving psychedelics and illicit drugs. For example, a 2021 study found that controlled doses of MDMA helped relieve some severe PTSD symptoms. “The theme here is using some aspects of reward and positivity to rewrite the negative components of our past,” Ramirez says. “It’s analogous to what we’re doing in rodents, except in humans—we artificially activated positive memories in rodents, and in humans, what they did was give them small doses of MDMA to see if that could be enough to rewrite some of the traumatic components of that experience.” These types of experiments point to the importance of continuing to explore the clinical and beneficial methods of memory manipulation, but it’s important to note that these experiments were done under close medical supervision and shouldn’t be attempted at home. For now, Ramirez is excited to see how this work can further push the boundaries in neuroscience, and hopes to see researchers experiment with even more out-of-the-box ideas that can transform medicine in the future: “We want game changers, right?” he says. “We want things that are going to be way more effective than the currently available treatment options. References: “Hippocampal cells segregate positive and negative engrams” by Monika Shpokayte, Olivia McKissick, Xiaonan Guan, Bingbing Yuan, Bahar Rahsepar, Fernando R. Fernandez, Evan Ruesch, Stephanie L. Grella, John A. White, X. Shawn Liu and Steve Ramirez, 26 September 2022, Communications Biology. DOI: 10.1038/s42003-022-03906-8 “Reactivating hippocampal-mediated memories during reconsolidation to disrupt fear” by Stephanie L. Grella, Amanda H. Fortin, Evan Ruesch, John H. Bladon, Leanna F. Reynolds, Abby Gross, Monika Shpokayte, Christine Cincotta, Yosif Zaki and Steve Ramirez, 12 September 2022, Nature Communications. DOI: 10.1038/s41467-022-32246-8 This work was supported by the National Institutes of Health. Scientists have found that verteporfin, a drug already approved by the FDA for eye disease, stopped the replication of SARS-CoV-2, the virus that causes COVID-19. An interdisciplinary research team led by the University of California, Los Angeles (UCLA) discovered that a drug already approved by the Food and Drug Administration (FDA) for eye disease, verteporfin, stopped the replication of SARS-CoV-2, the virus that causes COVID-19. Their laboratory study identified the Hippo signaling pathway as a potential target for therapies against the coronavirus. Background Many important human biological processes are controlled by complicated chain reactions called signaling pathways, in which certain proteins act as messenger molecules that promote or block the signals of other proteins. The lead researchers were investigating the Hippo pathway, which controls the size of organs in the body, in earlier National Institutes of Health–funded studies of the Zika virus, which can cause undersized brains in infants. Noticing that this pathway also seemed to have virus-fighting effects, they launched the current study investigating SARS-CoV-2. This chart shows levels of SARS-CoV-2 and deactivated YAP (pYAP127) in healthy cultured cells (mock) and cultured cells infected with the original strain of COVID-19 (SARS-CoV-2 Parental) and the Delta strain (SARS-CoV-2 Delta). Asterisks in the insets indicate uninfected cells. Credit: UCLA/Broad Stem Cell Research Center Method The scientists performed experiments using tissue samples from people with COVID-19, as well as cultured human heart and lung cells selected to closely reflect how healthy cells respond to SARS-CoV-2 infection. They observed changes in many genes involved with the Hippo signaling pathway after infection. In addition, they examined a protein called YAP, or Yes-associated protein, whose activity is blocked when the Hippo pathway is activated. The scientists found that in the cultured human cells, both the original strain and Delta variant of SARS-CoV-2 activated the Hippo pathway in the first few days after infection. When they silenced this pathway and increased YAP, the virus replicated itself more. They team also pretreated cells with verteporfin, which blocks YAP in the eye disease known as choroidal neovascularization, and then infected them with SARS-CoV-2. In the verteporfin-treated cells, concentrations of the coronavirus were below detectable levels, compared to more than 60,000 units of the virus per milliliter in an untreated control group. Impact The results indicate verteporfin may be a candidate to treat COVID-19, and its status as FDA-approved could make it easier to launch clinical trials to verify its safety and effectiveness against the coronavirus. The study showed that the Hippo pathway is activated within days of SARS-CoV-2 infection, suggesting that treatments using the mechanism could be deployed before symptoms arise to reduce the severity of disease. Reference: “Hippo signaling pathway activation during SARS-CoV-2 infection contributes to host antiviral response” by Gustavo Garcia Jr., Arjit Vijey Jeyachandran, Yijie Wang, Joseph Ignatius Irudayam, Sebastian Castillo Cario, Chandani Sen, Shen Li, Yunfeng Li, Ashok Kumar, Karin Nielsen-Saines, Samuel W. French, Priya S. Shah, Kouki Morizono, Brigitte N. Gomperts, Arjun Deb, Arunachalam Ramaiah, Vaithilingaraja Arumugaswami, 8 November 2022, PLOS Biology. DOI: 10.1371/journal.pbio.3001851 The study’s first author is Gustavo Garcia Jr., a former UCLA staff research associate, and the corresponding authors are Vaithilingaraja Arumugaswami, a UCLA associate professor of molecular and medical pharmacology and a member of the California NanoSystems Institute at UCLA and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, and Arunachalam Ramaiah of the Tata Institute for Genetics and Society in India. Other co-authors are Arjit Jeyachandran, Yijie Wang, Joseph Irudayam, Sebastian Castillo Cario, Chandani Sen, Shen Li, Yunfeng Li, Karin Nielsen-Saines, Samuel French, Kouki Morizono, Brigitte Gomperts, and Arjun Deb, all of UCLA; Ashok Kumar of Wayne State University; and Priya Shah of UC Davis. The study was funded by the UCLA David Geffen School of Medicine, the Broad Stem Cell Research Center, the UCLA W.M. Keck Foundation COVID-19 Research Award Program, the National Institutes of Health (NIH), and the Tata Institute. Photosynthesis is the process through which plants and other organisms transform light energy into chemical energy. Photosystem I in Plants Reveals a Hitherto Unobserved Face/Molecular Examination With High Precision Photosynthesis is the most important foundation of life on Earth. In it, biomass and sugar are produced from the sunlight’s energy by plants and single-celled algae. Oxygen is also released throughout this process. Now, for the first time, the structure of a novel protein complex that catalyzes energy conversion processes in photosynthesis has been determined by plant biotechnologists and structural biologists from the Universities of Münster (Germany) and Stockholm (Sweden). This protein complex is the photosystem I, which is known as a single protein complex (monomer) in plants. Professor Michael Hippler of the University of Münster and Professor Alexey Amunts of the University of Stockholm led a team of researchers that demonstrated for the first time that two photosystem I monomers in plants may come together as a dimer and described the molecular structure of this new kind of molecular machine. The findings, which have been recently published in the journal Nature Plants, provide molecular insights into the process of photosynthesis with a hitherto unparalleled degree of precision. They might help to make use of the reductive force (the willingness to give up electrons) of photosystem I more effectively in the future, for example, to produce hydrogen as a source of energy. The background: There are two photosynthesis complexes, called photosystems I and II, which work at their best in the case of light with different wavelengths. The uptake of light energy into photosystems I and II enable electrons to be transported within the molecular “photosynthetic machine”, thus driving the conversion of light energy into chemical energy. In the process, electrons from photosystem I are transmitted to the protein ferredoxin. In green algae, ferredoxin can transmit electrons arising during photosynthesis to an enzyme called hydrogenase, which then produces molecular hydrogen. This molecular hydrogen is thus produced by the input of light energy, which means it is produced renewably and might be able to act as a future source of energy. The researchers asked themselves the question: “How does the production of photosynthetic hydrogen relate to the structural dynamics of the monomer and dimer photosystem I? The Results in Detail The photosystem I homodimer from the green alga Chlamydomonas reinhardtii consists of 40 protein subunits with 118 transmembrane helices providing a structure for 568 photosynthesis pigments. Using cryogenic electron microscopy, the researchers showed that the absence of subunits with the designation PsaH and Lhca2 leads to a head-to-head orientation of monomer photosystem I (PSI) and its associated light-harvesting proteins (LHCI). The light-harvesting protein Lhca9 is the key element providing for this dimerization. In the study, the researchers define the most precisely available PSI-LHCI model to a resolution of 2.3 Ångström (one Ångström corresponds to one ten-millionth of a millimeter), including the flexibly bound electron transmitter plastocyanin, and they allocate the correct identity and orientation to all pigments, as well as to 621 water molecules which influence the energy transmission pathways. In connection with the loss of a second gene (pgr5), the genetically induced down-regulation of the subunit Lhca2 results in the very efficient production of hydrogen in the double mutant. As Michael Hippler says, “The depletion of Lhca2 promotes the formation of PSI dimer, and so we suggest that the hydrogenase may favor the targeting of photosynthetic electrons from the PSI dimer, as we proposed in our earlier work. The structure of the PSI dimer enables us to make targeted genetic modifications in order to test the hypothesis of improved hydrogen production through the PSI dimer.” Reference: “Algal photosystem I dimer and high-resolution model of PSI-plastocyanin complex” by Andreas Naschberger, Laura Mosebach, Victor Tobiasson, Sebastian Kuhlgert, Martin Scholz, Annemarie Perez-Boerema, Thi Thu Hoai Ho, André Vidal-Meireles, Yuichiro Takahashi, Michael Hippler, and Alexey Amunts, 13 October 2022, Nature Plants. DOI: 10.1038/s41477-022-01253-4 RE98915RGPOIOKJ 藍家割包會踩雷嗎? 》台北夜市美食特輯|10家真實體驗分享圓環邊蚵仔煎在地人怎麼說? 》台北夜市美食攻略|精選10間超人氣餐廳,一次帶你吃遍熱門口袋名單圓環邊蚵仔煎回訪率高嗎? 》台北小吃真的好吃嗎?10家餐廳真實評比 |
|||||||||||||||||||||||||||||||||||||||||||||
| ( 休閒生活|雜記 ) |























